85 related articles for article (PubMed ID: 15713992)
1. Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants.
Bensinger WI; Buckner CD; Lilleby K; Holmberg L; Storb R; Slattery JT
Oncology; 2004; 67(5-6):368-75. PubMed ID: 15713992
[TBL] [Abstract][Full Text] [Related]
2. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Demirer T; Buckner CD; Appelbaum FR; Bensinger WI; Sanders J; Lambert K; Clift R; Fefer A; Storb R; Slattery JT
Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
[TBL] [Abstract][Full Text] [Related]
3. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
4. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Demirer T; Buckner CD; Appelbaum FR; Lambert K; Bensinger WI; Clift R; Storb R; Slattery JT
Bone Marrow Transplant; 1996 Mar; 17(3):341-6. PubMed ID: 8704684
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
Takamatsu Y; Ogata K; Yamauchi K; Hara S; Kamimura T; Hayashi S; Suzumiya J; Tamura K
Jpn J Clin Oncol; 2005 Jul; 35(7):400-3. PubMed ID: 15976066
[TBL] [Abstract][Full Text] [Related]
6. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
7. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer.
Klumpp TR; Mangan KF; Glenn LD; Macdonald JS
Bone Marrow Transplant; 1993 Apr; 11(4):337-9. PubMed ID: 8097937
[TBL] [Abstract][Full Text] [Related]
8. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
Clopés A; Sureda A; Sierra J; Queraltó JM; Broto A; Farré R; Moreno E; Brunet S; Martino R; Mangues MA
Eur J Haematol; 2006 Jul; 77(1):1-6. PubMed ID: 16573745
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.
Bolinger AM; Zangwill AB; Slattery JT; Glidden D; DeSantes K; Heyn L; Risler LJ; Bostrom B; Cowan MJ
Bone Marrow Transplant; 2000 May; 25(9):925-30. PubMed ID: 10800058
[TBL] [Abstract][Full Text] [Related]
10. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
11. Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine.
de Castro FA; Simões BP; Godoy AL; Bertagnoli Trigo FM; Coelho EB; Lanchote VL
J Clin Pharmacol; 2016 Dec; 56(12):1555-1562. PubMed ID: 27130252
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
[TBL] [Abstract][Full Text] [Related]
13. Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation study.
Beelen DW; Sayer HG; Franke M; Scheulen ME; Quabeck K; Mohnke M; Oidtmann M; Schaefer UW
Bone Marrow Transplant; 1993 Oct; 12(4):363-70. PubMed ID: 8275036
[TBL] [Abstract][Full Text] [Related]
14. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.
Bolinger AM; Zangwill AB; Slattery JT; Risler LJ; Sultan DH; Glidden DV; Norstad D; Cowan MJ
Bone Marrow Transplant; 2001 Dec; 28(11):1013-8. PubMed ID: 11781609
[TBL] [Abstract][Full Text] [Related]
15. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
16. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
17. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Schiffman KS; Bensinger WI; Appelbaum FR; Rowley S; Lilleby K; Clift RA; Weaver CH; Demirer T; Sanders JE; Petersdorf S; Gooley T; Weiden P; Zuckerman N; Montgomery P; Maziarz R; Klarnet JP; Rivkin S; Trueblood K; Storb R; Holmberg L; Buckner CD
Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R; Pérez-Simón JA; Moreno E; Queraltó JM; Caballero D; Mateos M; Sureda A; Cañizo C; Brunet S; Briones J; Vazquez L; Clopés A; San Miguel JF; Sierra J
Biol Blood Marrow Transplant; 2005 Jun; 11(6):437-47. PubMed ID: 15931632
[TBL] [Abstract][Full Text] [Related]
20. Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation.
van der Jagt RH; Pari G; McDiarmid SA; Boisvert DM; Huebsch LB
Bone Marrow Transplant; 1994 Feb; 13(2):203-7. PubMed ID: 8205090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]